AR119753A1 - Agonistas no peptídicos del receptor de la somatostatina tipo 5 y usos de los mismos - Google Patents
Agonistas no peptídicos del receptor de la somatostatina tipo 5 y usos de los mismosInfo
- Publication number
- AR119753A1 AR119753A1 ARP200102284A ARP200102284A AR119753A1 AR 119753 A1 AR119753 A1 AR 119753A1 AR P200102284 A ARP200102284 A AR P200102284A AR P200102284 A ARP200102284 A AR P200102284A AR 119753 A1 AR119753 A1 AR 119753A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- fluoroalkyl
- alkyl
- heteroalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una sal o solvato del mismo aceptable desde el punto de vista farmacéutico, caracterizado porque: el Anillo A es carbociclo o heterociclo; X es N o C-Rᵃ; Y es N o C-Rᵇ; Z es N o C-Rᶜ; Rᵃ, Rᵇ, y Rᶜ son cada uno independientemente hidrógeno, halógeno, -CN, -N(R⁹)₂, -ORᶠ, -CO₂R⁹, -C(=O)N(R⁹)₂, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, fluoroalcoxi C₁₋₆ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, carbociclo monocíclico sustituido o no sustituido, o heterociclo monocíclico sustituido o no sustituido; Rᶠ es -L¹-Rᵍ; L¹ está ausente, es alquileno C₁₋₆, fluoroalquileno C₁₋₆, o heteroalquileno C₁₋₆; Rᵍ es hidrógeno, cicloalquilo C₃₋₆ sustituido o no sustituido, fenilo sustituido o no sustituido, -CO₂R⁹, o -C(=O)N(R⁹)₂, heterociclo monocíclico sustituido o no sustituido; R¹ y R² son independientemente hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, cicloalquilo C₃₋₆ sustituido o no sustituido, o heterocicloalquilo C₃₋₅ sustituido o no sustituido; R³ es hidrógeno, -CN, -CO₂R⁹, -C(=O)N(R⁹)₂, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, alcoxi C₁₋₆ sustituido o no sustituido, fluoroalcoxi C₁₋₆ sustituido o no sustituido, o heteroalquilo C₁₋₆ sustituido o no sustituido; R⁴ y R⁵ son cada uno independientemente hidrógeno, halógeno, -OR⁹, -N(R⁹)₂, -CN, -CO₂R⁹, -C(=O)N(R⁹)₂, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, alcoxi C₁₋₆ sustituido o no sustituido, fluoroalcoxi C₁₋₆ sustituido o no sustituido, o heteroalquilo C₁₋₆ sustituido o no sustituido; R⁶ es alquilo C₁₋₈ sustituido o no sustituido, fluoroalquilo C₁₋₈ sustituido o no sustituido, heteroalquilo C₁₋₈ sustituido o no sustituido, o -L²-R⁶ᵃ; L² está ausente, es alquileno C₁₋₈ sustituido o no sustituido, o -CHR⁶ᵇ-; R⁶ᵃ es cicloalquilo C₃₋₁₀ sustituido o no sustituido, arilo C₆₋₁₀ sustituido o no sustituido, heterocicloalquilo C₂₋₁₀ sustituido o no sustituido, o heteroarilo C₁₋₉ sustituido o no sustituido; R⁶ᵇ es hidrógeno, alquilo C₁₋₆, fluoroalquilo C₁₋₆, o cicloalquilo C₃₋₆ sustituido o no sustituido; R⁷ es hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, cicloalquilo C₃₋₁₀ sustituido o no sustituido, arilo C₆₋₁₀ sustituido o no sustituido, heterocicloalquilo C₂₋₁₀ sustituido o no sustituido, o heteroarilo C₁₋₉ sustituido o no sustituido; o R⁶ y R⁷ se toman junto con el nitrógeno al cual ellos están enlazados a fin de formar un heterociclo que contiene N sustituido o no sustituido; cada R⁸, R¹¹, y R¹² es independientemente hidrógeno, halógeno, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, carbociclo monocíclico sustituido o no sustituido, heterociclo monocíclico sustituido o no sustituido, -CN, -OR⁹, -C(=O)R¹⁰, -CO₂R⁹, -C(=O)N(R⁹)₂, -N(R⁹)₂, -NR⁹C(=O)R¹⁰, -NR⁹C(=O)OR¹⁰, -NR⁹C(=O)N(R⁹)₂, -C(R⁹)=N-OR⁹, -SR⁹, -S(=O)R⁹, -SO₂R⁹, o -SO₂N(R⁹)₂; o R¹¹ se toma junto con un R⁸ adyacente y los átomos enlazan el R¹¹ y el R⁸ adyacente a fin de formar un carbociclo fusionado sustituido o no sustituido, o un heterociclo fusionado sustituido o no sustituido; cada R⁹ es independientemente hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, cicloalquilo C₃₋₇ sustituido o no sustituido, heterocicloalquilo monocíclico de 3 a 8 elementos sustituido o no sustituido, fenilo sustituido o no sustituido, y heteroarilo monocíclico sustituido o no sustituido; o dos R⁹ en el mismo átomo N se toman junto con el átomo N al cual ellos están enlazados a fin de formar un heterociclo que contiene N sustituido o no sustituido; cada R¹⁰ es independientemente alquilo C₁₋₆ sustituido o no sustituido, fluoroalquilo C₁₋₆ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, cicloalquilo C₃₋₇ sustituido o no sustituido, heterocicloalquilo monocíclico de 3 a 8 elementos sustituido o no sustituido, fenilo sustituido o no sustituido, y heteroarilo monocíclico sustituido o no sustituido; y n es de 0 a 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886764P | 2019-08-14 | 2019-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119753A1 true AR119753A1 (es) | 2022-01-12 |
Family
ID=74568328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102284A AR119753A1 (es) | 2019-08-14 | 2020-08-12 | Agonistas no peptídicos del receptor de la somatostatina tipo 5 y usos de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11479540B2 (es) |
| EP (1) | EP4013748A4 (es) |
| JP (1) | JP2022544055A (es) |
| KR (1) | KR20220047318A (es) |
| CN (1) | CN114585614A (es) |
| AR (1) | AR119753A1 (es) |
| AU (1) | AU2020327950A1 (es) |
| BR (1) | BR112022002683A2 (es) |
| CA (1) | CA3149840A1 (es) |
| CL (1) | CL2022000354A1 (es) |
| CO (1) | CO2022002781A2 (es) |
| IL (1) | IL290479A (es) |
| MX (1) | MX2022001874A (es) |
| PE (1) | PE20221402A1 (es) |
| WO (1) | WO2021030262A1 (es) |
| ZA (1) | ZA202201829B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
| EP3853218A4 (en) | 2018-09-18 | 2022-02-16 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND USES THEREOF |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| MX2022001874A (es) | 2019-08-14 | 2022-03-11 | Crinetics Pharmaceuticals Inc | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. |
| WO2022177988A1 (en) * | 2021-02-17 | 2022-08-25 | Crinetics Pharmaceuticals, Inc. | Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism |
| US11773076B2 (en) | 2021-02-17 | 2023-10-03 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of a somatostatin modulator |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2024089668A1 (en) * | 2022-10-28 | 2024-05-02 | Basecamp Bio Inc. | Somatostatin receptor 2 agonists and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127343A (en) | 1996-05-14 | 2000-10-03 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| US20090258853A1 (en) | 2006-03-13 | 2009-10-15 | Brian Eastman | Somatostatin Agonists |
| EP2054385A2 (en) * | 2006-08-15 | 2009-05-06 | F. Hoffmann-Roche AG | Phenyl, pyridine and quinoline derivatives |
| EP2211619A1 (en) | 2007-10-18 | 2010-08-04 | Merck Sharp & Dohme Corp. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| CA2729220A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | Di-substituted phenyl compounds |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
| EP2571356A4 (en) | 2010-05-18 | 2013-11-20 | Merck Sharp & Dohme | SPIROISOXAZOLIN COMPOUNDS AS SSTR5 ANTAGONISTS |
| GB201008290D0 (en) | 2010-05-18 | 2010-06-30 | Syngenta Ltd | Chemical compounds |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| JP6380402B2 (ja) | 2013-09-30 | 2018-08-29 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| CN105579524B (zh) | 2013-10-02 | 2018-05-04 | 株式会社可乐丽 | 树脂组合物、多层片、包装材料和容器 |
| KR102324042B1 (ko) | 2016-07-14 | 2021-11-09 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 및 그의 용도 |
| EP3581569A4 (en) | 2017-02-08 | 2020-02-19 | ONO Pharmaceutical Co., Ltd. | CONNECTION WITH AGONISTIC SOMATOSTATIN RECEPTOR ACTIVITY AND PHARMACEUTICAL USE THEREOF |
| JP7106564B2 (ja) | 2017-03-16 | 2022-07-26 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレータとその使用 |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
| EP3853218A4 (en) | 2018-09-18 | 2022-02-16 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND USES THEREOF |
| MX2022001874A (es) | 2019-08-14 | 2022-03-11 | Crinetics Pharmaceuticals Inc | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. |
-
2020
- 2020-08-10 MX MX2022001874A patent/MX2022001874A/es unknown
- 2020-08-10 BR BR112022002683A patent/BR112022002683A2/pt unknown
- 2020-08-10 PE PE2022000232A patent/PE20221402A1/es unknown
- 2020-08-10 CN CN202080072298.0A patent/CN114585614A/zh active Pending
- 2020-08-10 KR KR1020227008059A patent/KR20220047318A/ko unknown
- 2020-08-10 CA CA3149840A patent/CA3149840A1/en active Pending
- 2020-08-10 AU AU2020327950A patent/AU2020327950A1/en active Pending
- 2020-08-10 US US16/989,193 patent/US11479540B2/en active Active
- 2020-08-10 WO PCT/US2020/045610 patent/WO2021030262A1/en unknown
- 2020-08-10 JP JP2022505634A patent/JP2022544055A/ja active Pending
- 2020-08-10 EP EP20851491.9A patent/EP4013748A4/en active Pending
- 2020-08-12 AR ARP200102284A patent/AR119753A1/es unknown
-
2022
- 2022-01-21 US US17/581,740 patent/US20220144802A1/en not_active Abandoned
- 2022-02-09 IL IL290479A patent/IL290479A/en unknown
- 2022-02-11 ZA ZA2022/01829A patent/ZA202201829B/en unknown
- 2022-02-11 CL CL2022000354A patent/CL2022000354A1/es unknown
- 2022-03-10 CO CONC2022/0002781A patent/CO2022002781A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220047318A (ko) | 2022-04-15 |
| WO2021030262A1 (en) | 2021-02-18 |
| US11479540B2 (en) | 2022-10-25 |
| IL290479A (en) | 2022-04-01 |
| PE20221402A1 (es) | 2022-09-15 |
| JP2022544055A (ja) | 2022-10-17 |
| ZA202201829B (en) | 2023-07-26 |
| AU2020327950A1 (en) | 2022-03-17 |
| CL2022000354A1 (es) | 2022-10-21 |
| CA3149840A1 (en) | 2021-02-18 |
| CO2022002781A2 (es) | 2022-06-21 |
| EP4013748A4 (en) | 2023-08-09 |
| TW202115008A (zh) | 2021-04-16 |
| BR112022002683A2 (pt) | 2022-07-05 |
| US20220144802A1 (en) | 2022-05-12 |
| US20210047287A1 (en) | 2021-02-18 |
| CN114585614A (zh) | 2022-06-03 |
| EP4013748A1 (en) | 2022-06-22 |
| MX2022001874A (es) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119753A1 (es) | Agonistas no peptídicos del receptor de la somatostatina tipo 5 y usos de los mismos | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
| AR114950A1 (es) | Compuestos de benzamida | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR115092A1 (es) | Inhibidores de magl | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| AR105575A1 (es) | COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa | |
| AR110089A1 (es) | Inhibidores de magl | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR068547A1 (es) | Derivados de quinolina | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR088630A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR115920A1 (es) | Inhibidores tipo indol y azaindol de enzimas pad | |
| AR119971A1 (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| AR102222A1 (es) | Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina |